Your browser doesn't support javascript.
loading
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Stevens, Mark M; Kimmerling, Robert J; Olcum, Selim; Vacha, Madeleine; LaBella, Rachel; Minnah, Anthony; Katsis, Katelin; Fujii, Juanita; Shaheen, Zayna; Sundaresan, Srividya; Criscitiello, Joseph; Niesvizky, Ruben; Raje, Noopur; Branagan, Andrew; Krishnan, Amrita; Jagannath, Sundar; Parekh, Samir; Sperling, Adam S; Rosenbaum, Cara A; Munshi, Nikhil; Luskin, Marlise R; Tamrazi, Anobel; Reid, Clifford A.
Afiliação
  • Stevens MM; Travera, Medford, MA.
  • Kimmerling RJ; Travera, Medford, MA.
  • Olcum S; Travera, Medford, MA.
  • Vacha M; Travera, Medford, MA.
  • LaBella R; Travera, Medford, MA.
  • Minnah A; Travera, Medford, MA.
  • Katsis K; Travera, Medford, MA.
  • Fujii J; Department of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA.
  • Shaheen Z; Department of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA.
  • Sundaresan S; Department of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA.
  • Criscitiello J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Niesvizky R; Weill Cornell Medicine, New York, NY.
  • Raje N; Massachusetts General Hospital, Boston, MA.
  • Branagan A; Massachusetts General Hospital, Boston, MA.
  • Krishnan A; City of Hope, Los Angeles, CA.
  • Jagannath S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Parekh S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Sperling AS; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Rosenbaum CA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Munshi N; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Luskin MR; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Tamrazi A; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Reid CA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
JCO Precis Oncol ; 8: e2300349, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38237098
ABSTRACT

PURPOSE:

Cancer patients with advanced-stage disease have poor prognosis, typically having limited options for efficacious treatment, and genomics-based therapy guidance continues to benefit only a fraction of patients. Next-generation ex vivo approaches, such as cell mass-based response testing (MRT), offer an alternative precision medicine approach for a broader population of patients with cancer, but validation of clinical feasibility and potential impact remain necessary. MATERIALS AND

METHODS:

We evaluated the clinical feasibility and accuracy of using live-cell MRT to predict patient drug sensitivity. Using a unified measurement workflow with a 48-hour result turnaround time, samples were subjected to MRT after treatment with a panel of drugs in vitro. After completion of therapeutic course, clinical response data were correlated with MRT-based predictions of outcome. Specimens were collected from 104 patients with solid (n = 69) and hematologic (n = 35) malignancies, using tissue formats including needle biopsies, malignant fluids, bone marrow aspirates, and blood samples. Of the 81 (78%) specimens qualified for MRT, 41 (51%) patients receiving physician-selected therapies had treatments matched to MRT.

RESULTS:

MRT demonstrated high concordance with clinical responses with an odds ratio (OR) of 14.80 (P = .0003 [95% CI, 2.83 to 102.9]). This performance held for both solid and hematologic malignances with ORs of 20.67 (P = .0128 [95% CI, 1.45 to 1,375.57]) and 8.20 (P = .045 [95% CI, 0.77 to 133.56]), respectively. Overall, these results had a predictive accuracy of 80% (P = .0026 [95% CI, 65 to 91]).

CONCLUSION:

MRT showed highly significant correlation with clinical response to therapy. Routine clinical use is technically feasible and broadly applicable to a wide range of samples and malignancy types, supporting the need for future validation studies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article